ArticleMicrobes and infection2008
A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.
Article in Microbes and infection, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Plant Extracts and SARS-CoV-2: Research and Applications.Life (Basel, Switzerland) · 2023Review
- Comparative Analysis and Identification of Spike Mutations in Iranian COVID-19 Samples from the First Three Waves of Disease.Advanced biomedical research · 2023Article
- An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation.Journal of molecular biology · 2022Article
- Long Term Immune Response Produced by the SputnikV Vaccine.International journal of molecular sciences · 2021Article
- Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.Viruses · 2021Review
- Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.Journal of medicinal chemistry · 2020Review
- How did we get here? Short history of COVID-19 and other coronavirus-related epidemics.Head & neck · 2020Article
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Article
- Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Viruses · 2012Review
- Identification and characterization of a neutralizing-epitope-containing spike protein fragment in turkey coronavirus.Archives of virology · 2011Article
- Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission.Journal of virology · 2010Review
- Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.The Journal of infectious diseases · 2010Article
- Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.Virology · 2009Article
- The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nature reviews. Microbiology · 2009Review
- Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.Microbiology and immunology · 2009Article
- Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to SARS-CoV infection, neutralizing antibodies are generated against the Spike (S) protein. Determination of the active regions that allow viral escape from neutralization would enable the use of these antibodies for future passive immunotherapy. We immunized mice with UV-inactivated SARS-CoV to generate three anti-S monoclonal antibodies, and established several neutralization escape mutants with S protein. We identified several amino acid substitutions, including Y442F and V601G in the S1 domain and D757N and A834V in the S2 region. In the presence of each neutralizing antibody, double mutants with substitutions in both domains exhibited a greater growth advantage than those with only one substitution. Importantly, combining two monoclonal antibodies that target different epitopes effected almost complete suppression of wild type virus replication. Thus, for effective passive immunotherapy, it is important to use neutralizing antibodies that recognize both the S1 and S2 regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.